Cost-effectiveness (CE) analysis of pembrolizumab as first-line (1L) treatment for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) in the United States (US).

被引：0
|
作者：
Ramakrishnan, Karthik
Jain, Disha
Gandhi, Jyotika
Chirovsky, Diana Romana
Borse, Rebekah
机构：
[1] Merck & Co Inc, Kenilworth, NJ USA
[2] CHEORS, N Wales, PA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.e18013
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e18013
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Final Analysis of the Phase 4 KEYNOTE-B10 Study: First-Line(1L) Pembrolizumab (pembro) plus Carboplatin (carbo) plus Paclitaxel (pacli) for Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC)
    Dzienis, M.
    Cundom, J.
    Fuentes, C. S.
    Spreafico, A.
    Nordlinger, M. J.
    Pastor, A. V.
    Alesi, E.
    Neki, A.
    Fung, A. S.
    Lima, I. P. Figueiredo
    Oppelt, P.
    da Cunha Junior, G. F.
    Franke, F. A.
    Tseng, J.
    Joshi, A. J.
    McCarthy, J.
    Sidi, Y.
    Gumuscu, B.
    Naicker, N.
    de Castro, G., Jr.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 118 (05): : E3 - E4
  • [32] Pembrolizumab (P) or P plus chemotherapy (C) versus EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): analysis of KEYNOTE-048 by disease state.
    Rischin, Danny
    Harrington, Kevin Joseph
    Greil, Richard
    Soulieres, Denis
    Tahara, Makoto
    Castro, Gilberto
    Psyrri, Amanda
    Baste, Neus
    Neupane, Prakash C.
    Bratland, Ase
    Fuereder, Thorsten
    Hughes, Brett Gordon Maxwell
    Mesia, Ricard
    Ngamphaiboon, Nuttapong
    Rordorf, Tamara
    Ishak, Wan Zamaniah Wan
    Lin, Jianxin
    Gumuscu, Burak
    Swaby, Ramona F.
    Burtness, Barbara
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [33] Comparative efficacy of pembrolizumab with carboplatin and paclitaxel as first-line (1L) therapy in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC): A network meta-analysis (NMA) with matching-adjusted indirect comparison (MAIC).
    Zheng, Dandan
    Mojebi, Ali
    Black, Christopher M.
    Giezek, Hilde
    Naicker, Niroshini
    Vanetta, Chiara
    Keeping, Sam
    Merchant, Sanjay
    Dzienis, Marcin Radoslaw
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [34] Pembrolizumab with or without chemotherapy for first-line treatment of recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): 5-year results from KEYNOTE-048
    Tahara, M.
    Greil, R.
    Rischin, D.
    Harrington, K. J.
    Burtness, B.
    De Castro, G., Jr.
    Psyrri, A.
    Brana, I.
    Neupane, P.
    Bratland, A.
    Fuereder, T.
    Hughes, B. G. M.
    Mesia Nin, R.
    Ngamphaiboon, N.
    Rordorf, T.
    Ishak, W. Z. Wan
    Lin, J.
    Gumuscu, B.
    Lerman, N.
    Soulieres, D.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S844 - S844
  • [35] Pembrolizumab (pembro) plus carboplatin (carbo) plus paclitaxel (pacli) as first-line (1L) therapy in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Phase VI KEYNOTE-B10 study
    Dzienis, M. R.
    Cundom, J. E.
    Fuentes, C. S.
    Hansen, A. R.
    Nordlinger, M. J.
    Pastor, A. V.
    Oppelt, P.
    Neki, A.
    Gregg, R. W.
    Lima, I. P. F.
    Franke, F. A.
    Da Cunha Junior, G. F.
    Tseng, J. E.
    Loree, T.
    Joshi, A. J.
    Mccarthy, J. S.
    Naicker, N.
    Sidi, Y.
    Gumuscu, B.
    De Castro, G., Jr.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S839 - S840
  • [36] CARBOPLATIN, PACLITAXEL AND PEMBROLIZUMAB FOR THE FIRST LINE TREATMENT OF RECURRENT AND/OR METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA
    Valadez, Angelica
    Welsh, Madeleine
    Kim, Christine
    Johns, Angela
    Algazi, Alain
    Kang, Hyunseok
    Kang, Hyunseok
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A118 - A118
  • [37] Cost-Effectiveness of Nivolumab in Recurrent Metastatic Head and Neck Squamous Cell Carcinoma
    Zargar, Mahdi
    McFarlane, Thomas
    Chan, Kelvin K. W.
    Wong, William W. L.
    ONCOLOGIST, 2018, 23 (02): : 225 - 233
  • [38] Cost-effectiveness of first-line enfortumab vedotin in addition to pembrolizumab for metastatic urothelial carcinoma in the United States
    Li, Andong
    Wu, Meiyu
    Xie, Ouyang
    Xiang, Heng
    Meng, Kehui
    Tan, Chongqing
    Wang, Long
    Wan, Xiaomin
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [39] LEAP-010: Phase III study of first-line pembrolizumab with or without lenvatinib in patients (pts) with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)
    Siu, L. L.
    Burtness, B.
    Cohen, E. E.
    Harrington, K. J.
    Licitra, L. F.
    Rischin, D.
    Zhu, Y.
    Okpara, C. E.
    Pinheiro, C.
    Swaby, R. F.
    Machiels, J-P.
    Tahara, M.
    ANNALS OF ONCOLOGY, 2020, 31 : S683 - S684
  • [40] Real-World Time on Treatment Analysis of Pembrolizumab Treated Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) Patients Stratified by ECOG PS in the United States
    Black, C.
    Wang, L.
    Ramakrishnan, K.
    Turzhitsky, V.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 114 (03): : E342 - E342
12345